Evaluation of efficacy in diabetes control of basal insulin plus SGLT-2 inhibitor/GLP-1 receptor agonist/ rapid insulin in patients with type 2 diabetes
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000024367
- Lead Sponsor
- Tokyo Women's Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1.Participants with severe liver dysfunction 2.Participants with severe renal dysfunction 3.Participants with severe diabetic complications 4.Participants who are pregnant, hope to be pregnant, or are in lactation period 5.Participants whose fasting serum C-peptide immunoreactivity below 0.5ng/ml 6.Participants whose postprandial serum C-peptide immunoreactivity below 0.5ng/ml
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in HbA1c after 52 weeks Change in weight after 52 weeks
- Secondary Outcome Measures
Name Time Method evel of self-monitoring of blood glucose Frequency of hypoglycemia Change in amount of insulin